Business context and reporting period
The filing is Tokai Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2016. This does not match the request metadata identifying Eledon Pharmaceuticals, Inc.; verify the issuer before relying on this summary. Tokai was a clinical-stage biopharmaceutical company focused on prostate cancer, with galeterone as its lead candidate and an early-stage androgen-receptor-degradation program.
Financial results and liquidity
Amounts below are in U.S. dollars; financial statement figures are reported in thousands.
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $9.895m | $5.855m | $17.826m | $16.414m |
| General and administrative expense | $3.680m | $3.127m | $7.229m | $5.868m |
| Net loss | $13.526m | $8.957m | $24.952m | $22.217m |
| Net loss per share | $0.60 | $0.40 | $1.10 | $0.99 |
| Operating cash used | Not stated for quarter | Not stated for quarter | $20.037m | $22.109m |
At June 30, 2016, cash and cash equivalents were $12.156m and marketable securities were $31.771m, totaling $43.927m; current assets were $46.186m and current liabilities $7.817m. Total liabilities were $7.973m; the filing reports no debt balance. The company had an accumulated deficit of $156.390m. Six-month investing activities provided $8.133m, primarily reflecting maturities of marketable securities; financing activities provided $0.037m. No profit or positive operating cash flow was reported.
Material changes versus prior comparable periods
Q2 operating expenses rose $4.593m year over year, with R&D up $4.040m, chiefly due to ARMOR3-SV trial activity, manufacturing validation, and companion-diagnostic work. Six-month operating expenses rose $2.773m, while net loss increased $2.735m. Six-month operating cash use improved by $2.072m year over year. Compared with December 31, 2015, cash and cash equivalents plus marketable securities fell from $63.957m to $43.927m.
Outlook, material events, and risks
After quarter-end, on July 26, 2016, Tokai announced it would discontinue its pivotal Phase 3 ARMOR3-SV trial following the independent monitoring committee’s conclusion that the trial was unlikely to meet its primary endpoint of improved radiographic progression-free survival versus enzalutamide in AR-V7-positive metastatic castration-resistant prostate cancer. The committee cited no safety concern. Management said it would analyze unblinded data and assess galeterone, the ARMOR2 expansion, planned studies, and its pipeline; it stated there was a substantial likelihood it would not pursue galeterone for AR-V7-positive disease.
On July 29, the company announced a workforce reduction of approximately 60%, to 10 full-time-equivalent employees. It expected approximately $1.3m in severance and related charges, substantially all in Q3 2016, and cited estimated annualized savings of approximately $4.2m once implemented. Management expected existing cash and investments to fund operations into at least the first half of 2017, but said estimates depended on uncertain plans and spending and that substantial additional funding would be needed for continued development or commercialization. Management was considering strategic alternatives, including partnerships, licensing or asset transactions, without committing to a course or timing.
On August 1, 2016, a purported shareholder filed a securities class action alleging misleading statements and omissions concerning galeterone trials; the company said it intended to defend the case and could not estimate potential losses. Other key risks include clinical and regulatory failure, dependence on outside manufacturers and trial providers, financing needs, intellectual-property uncertainty, and disruption following the workforce reduction. The company reported effective disclosure controls as of June 30, 2016.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is Tokai Pharmaceuticals, Inc., not Eledon Pharmaceuticals, Inc.
- Review subsequent disclosures of ARMOR3-SV unblinded results and management’s decisions on galeterone, ARMOR2, and the remaining pipeline.
- Verify actual cash runway, spending reductions, severance costs, and any financing or strategic transactions after the announced restructuring.
- Track the shareholder lawsuit’s status and any developments affecting potential financial exposure.
- Assess whether the filing’s estimate of funding into at least the first half of 2017 remains applicable given the revised development plans.